• DNase I (RNase-free): Reliable DNA Removal for RNA Workflows

  2026-05-15

  DNase I (RNase-free) from APExBIO sets the benchmark for precise DNA removal in RNA-focused protocols, ensuring high yield and purity, even in complex 3D culture models. Discover how its optimized activity, proven in leading-edge cancer research, streamlines workflows and addresses the most persistent contamination challenges.

• Super-Enhancer Regulation of Disulfidptosis in Prostate Canc

  2026-05-15

  This study reveals how super-enhancers drive SLC7A11 expression via FOXA1, enabling disulfidptosis in prostate cancer cells under metabolic stress. The findings highlight the SE/FOXA1/SLC7A11 axis as a promising therapeutic target and provide mechanistic insight into cell death regulation in advanced prostate malignancy.

• Anlotinib Hydrochloride: Multi-Target Tyrosine Kinase Inhibi

  2026-05-14

  Unlock advanced anti-angiogenic and anti-proliferative research with Anlotinib hydrochloride, a next-generation multi-target tyrosine kinase inhibitor. This guide delivers actionable protocols, practical troubleshooting, and performance comparisons to optimize your cancer research assays and translational workflows.

• Applied Protocols with Anlotinib Hydrochloride: Cancer Resea

  2026-05-14

  Anlotinib hydrochloride is redefining angiogenesis and proliferation assays with unmatched selectivity across VEGFR2, PDGFRβ, and FGFR1 pathways. Discover how this multi-target tyrosine kinase inhibitor streamlines experimental workflows, elevates reproducibility, and brings translational impact to advanced cancer research.

• Protein A/G Magnetic Co-IP/IP Kit: Precision in Protein Comp

  2026-05-13

  Unlock robust co-immunoprecipitation and antibody purification workflows with the Protein A/G Magnetic Co-IP/IP Kit. This magnetic bead platform maximizes assay reproducibility and minimizes protein degradation, enabling researchers to dissect protein-protein interactions and SUMOylation events with clarity.

• Bortezomib (PS-341): Optimizing Proteasome Inhibition Workfl

  2026-05-13

  Bortezomib (PS-341) empowers researchers to dissect proteasome-regulated cellular processes with high specificity, enabling robust apoptosis assays and translational insights for multiple myeloma and mantle cell lymphoma research. This guide integrates cutting-edge protocol parameters, troubleshooting strategies, and new findings on thymic regeneration, maximizing the experimental impact of APExBIO’s benchmark proteasome inhibitor.

• Anlotinib Hydrochloride Suppresses Tumor Angiogenesis via VE

  2026-05-12

  A recent study demonstrates that Anlotinib hydrochloride, a multi-target tyrosine kinase inhibitor, potently suppresses angiogenesis by inhibiting VEGFR2, PDGFRβ, and FGFR1 activation in vitro and in vivo. These findings provide mechanistic insight and experimental benchmarks for advanced anti-angiogenic strategies in cancer research.

• AT-406 (SM-406): Protocols and Troubleshooting in Apoptosis

  2026-05-12

  AT-406 (SM-406) is a potent, orally bioavailable IAP antagonist that empowers researchers to dissect apoptosis mechanisms and sensitize cancer cells to therapy. This guide delivers actionable, evidence-driven protocols, troubleshooting strategies, and advanced use-cases—helping oncology labs maximize data quality and translational relevance.

• Diclofenac and Intestinal Organoids: Next-Gen Inflammation M

  2026-05-11

  Explore how Diclofenac, a non-selective COX inhibitor, is powering a new wave of translational inflammation and pain signaling research through its integration with human pluripotent stem cell-derived intestinal organoids. This article provides mechanistic insights, protocol guidance, and a strategic roadmap for maximizing the impact of Diclofenac in advanced pharmacokinetic and anti-inflammatory drug research, addressing the limitations of legacy in vitro models and elevating experimental reproducibility.

• Ruxolitinib (INCB018424): Optimizing Myeloproliferative Diso

  2026-05-11

  Ruxolitinib (INCB018424) enables high-fidelity inhibition of the JAK-STAT pathway, transforming both myeloproliferative disorder and immunomodulatory oncology research. This article delivers detailed workflows, spectral cytometry integration, and troubleshooting intelligence, all grounded in the latest high-dimensional immune profiling evidence.

• SM-102 in mRNA Vaccine LNPs: Predictive Design Meets Practic

  2026-05-10

  Explore the pivotal role of SM-102 in mRNA delivery, focusing on machine learning-enabled predictive design and practical assay considerations. This in-depth analysis reveals how SM-102's unique properties fuel innovation in mRNA vaccine delivery systems.

• Anlotinib Hydrochloride: Mechanistic Power for Translational

  2026-05-09

  This thought-leadership article dissects the mechanistic underpinnings, experimental validation, and translational strategies surrounding Anlotinib hydrochloride—a multi-target tyrosine kinase inhibitor—and its pivotal role in modern angiogenesis and tumor biology research. We integrate clinical case evidence, protocol guidance, and workflow recommendations to empower translational scientists with actionable insights, building upon and extending existing literature. Cited numeric claims are consistently attributed in HTML, protocol parameters are structured, and the discussion is anchored in APExBIO’s product reliability.

• Septin4 Promotes HIF-1α Degradation and Aggravates Hypoxic C

  2026-05-09

  This study uncovers a novel mechanism by which Septin4 exacerbates hypoxia-induced cardiomyocyte apoptosis through VHL-mediated ubiquitination and degradation of HIF-1α. These findings expand our understanding of the molecular regulation of hypoxic injury and may inform future strategies for myocardial ischemia intervention.

• AT-406 (SM-406): Reliable Solutions for Apoptosis Assays

  2026-05-08

  This authoritative guide demonstrates how AT-406 (SM-406) (SKU A3019) addresses common laboratory challenges in apoptosis pathway activation and cancer research. By integrating validated protocols, mechanistic insights, and hands-on workflow recommendations, scientists can optimize assay reliability and data reproducibility with confidence.

• Anlotinib Hydrochloride: Advanced Multi-Target TKI in Angiog

  2026-05-07

  Anlotinib hydrochloride is redefining anti-angiogenic research by delivering nanomolar potency, high selectivity for VEGFR2, PDGFRβ, and FGFR1, and robust performance in migration and tube formation assays. This guide details evidence-backed workflows, protocol optimizations, and troubleshooting strategies for maximizing reproducibility and insight in cancer research.

16264 records 1/1085 page Next 12345 下5页 Last page